Current options for the treatment of resistant hypertension

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 11, 2009, Pages 1385-1393

  Ahmed, Mustafa I ^a   Pisoni, Roberto ^a   Calhoun, David A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Antihypertensives; Blood pressure; Pseudoresistant hypertension; Resistant hypertension

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ALDOSTERONE; AMPHETAMINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANOREXIGENIC AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; COCAINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FUROSEMIDE; GESTAGEN; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; METHYLPHENIDATE; MINERALOCORTICOID ANTAGONIST; MODAFINIL; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG;

AEROBIC EXERCISE; ALCOHOLISM; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY ARTERY STENOSIS; LIFESTYLE MODIFICATION; LOW DRUG DOSE; OBESITY; PATIENT COMPLIANCE; PHEOCHROMOCYTOMA; PHYSICAL ACTIVITY; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

ALCOHOL DRINKING; ANTIHYPERTENSIVE AGENTS; DIURETICS; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; LIFE STYLE; OBESITY; SODIUM, DIETARY; TREATMENT FAILURE; WEIGHT LOSS;

EID: 73349133730     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.120     Document Type: Review

References (87)

1. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 117(25), e510-e526 (2008). •• Most comprehensive review on the subject of resistant hypertension covering all key aspects of diagnosis, evaluation and treatment.
2. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mmHg. JAMA (202), 1038-1044 (1967).
3. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two universitybased cohorts. Am. J. Hypertens. 18(5 Pt 1), 619-626 (2005).
4. Hermida RC, Ayala DE, Calvo C et al. Effects of time of day of treatment on ambulatory blood pressure pattern of patients with resistant hypertension. Hypertension 46(4), 1053-1059 (2005).
5. Pickering TG, Hall JE, Appel LJ et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 111(5), 697-716 (2005).
6. Yiannakopoulou E, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur. J. Cardiovasc. Prev. Rehabil. 12(3), 243-249 (2005).
7. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J. Hypertens. 23(11), 2101-2107 (2005).
8. Amado P, Vasconcelos N, Santos I, Almeida L, Nazare J, Carmona J. Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect". Rev. Port. Cardiol. 18(10), 897-906 (1999).
9. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am. J. Hypertens. 14(12), 1263-1269 (2001).
10. Pierdomenico SD, Lapenna D, Bucci A et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am. J. Hypertens. 18(11), 1422-1428 (2005).
11. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 31(2), 712-718 (1998).
12. Mancia G, Bombelli M, Facchetti R et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 54(2), 226-232 (2009).
13. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch. Intern. Med. 168(21), 2340-2346 (2008). • Highlights the prognostic importance of office and ambulatory blood pressures in patients with resistant hypertension
14. Forman JP, Stampfer MJ, Curhan GC. Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 46(3), 500-507 (2005).
15. Radack K, Deck C. Do nonsteroidal anti-inflammatory drugs interfere with blood pressure control in hypertensive patients? J. Gen. Intern. Med. 2(2), 108-112 (1987).
16. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 39(4), 929-934 (2002).
17. Chasan-Taber L, Willett WC, Manson JE et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 94(3), 483-489 (1996).
18. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-β-estradiol, in postmenopausal women with hypertension. Hypertension 48(2), 246-253 (2006).
19. Bramlage P, Pittrow D, Wittchen HU et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am. J. Hypertens. 17(10), 904-910 (2004).
20. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am. J. Hypertens. 18(6), 805-812 (2005).
21. Aucott L, Poobalan A, Smith WC, Avenell A, Jung R, Broom J. Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review. Hypertension 45(6), 1035-1041 (2005).
22. Neter JE, Stam BE, Kok FJ, Grobbee DE, Geleijnse JM. Influence of weight reduction on blood pressure: a metaanalysis of randomized controlled trials. Hypertension 42(5), 878-884 (2003).
23. Weinberger MH, Cohen SJ, Miller JZ, Luft FC, Grim CE, Fineberg NS. Dietary sodium restriction as adjunctive treatment of hypertension. JAMA 259(17), 2561-2565 (1988).
24. Boudville N, Ward S, Benaroia M, House AA. Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am. J. Hypertens. 18(10), 1300-1305 (2005).
25. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J. Am. Coll. Cardiol. 52(22), 1749-1757 (2008).
26. Henningsen NC, Ohlsson O, Mattiasson I, Trell E, Kristensson H, Hood B. Hypertension, levels of serum gamma glutamyl transpeptidase and degree of blood pressure control in middle-aged males. Acta Med. Scand. 207(4), 245-251 (1980).
27. Aguilera MT, de la Sierra A, Coca A, Estruch R, Fernandez-Sola J, Urbano-Marquez A. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension 33(2), 653-657 (1999).
28. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42(6), 1206-1252 (2003).
29. Whelton SP, Chin A, Xin X, He J. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann. Intern. Med. 136(7), 493-503 (2002).
30. Appel LJ, Moore TJ, Obarzanek E et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. 336(16), 1117-1124 (1997).
31. Pimenta E, Calhoun DA, Oparil S. Mechanisms and treatment of resistant hypertension. Arq. Bras. Cardiol. 88(6), 683-692 (2007).
32. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N. Engl. J. Med. 342(19), 1378-1384 (2000).
33. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 290(14), 1906-1914 (2003).
34. Logan AG, Perlikowski SM, Mente A et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J. Hypertens. 19(12), 2271-2277 (2001). • Study demonstrating the high prevalence of obstructive sleep apnea in patients with resistant hypertension.
35. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131(2), 453-459 (2007). •• Highlights a significant association between plasma aldosterone and obstructive sleep apnea in patients with resistant hypertension but not control subjects.
36. Grote L, Hedner J, Peter JH. Sleep-related breathing disorder is an independent risk factor for uncontrolled hypertension. J. Hypertens. 18(6), 679-685 (2000).
37. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J. Clin. Invest. 96(4), 1897-1904 (1995).
38. Grassi G, Facchini A, Trevano FQ et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension 46(2), 321-325 (2005).
39. Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125(1), 112-117 (2004).
40. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 43(3), 518-524 (2004).
41. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch. Intern. Med. 168(11), 1159-1164 (2008). •• Demonstrates that aldosterone levels are higher and, furthermore, that there is evidence of intravascular volume expansion (higher brain-type and atrial natriuretic peptide levels) in patients with resistant hypertension when compared with controls.
42. Lim PO, Rodgers P, Cardale K, Watson AD, MacDonald TM. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353(9146), 40 (1999).
43. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J. Hum. Hypertens. 14(5), 311-315 (2000).
44. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40(6), 892-896 (2002).
45. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am. J. Kidney Dis. 37(4), 699-705 (2001).
46. Mosso L, Carvajal C, Gonzalez A et al. Primary aldosteronism and hypertensive disease. Hypertension 42(2), 161-165 (2003).
47. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin. Chem. 51(2), 386-394 (2005).
48. Fardella CE, Mosso L, Gomez-Sanchez C et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J. Clin. Endocrinol. Metab. 85(5), 1863-1867 (2000).
49. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am. J. Hypertens. 16(11 Pt 1), 925-930 (2003).
50. Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin. Proc. 56(6), 354-360 (1981).
51. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 366(9486), 665-675 (2005).
52. Aqel RA, Zoghbi GJ, Baldwin SA et al. Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. J. Hypertens. 21(6), 1157-1162 (2003).
53. Safian RD, Textor SC. Renal-artery stenosis. N. Engl. J. Med. 344(6), 431-442 (2001).
54. Aqel R, AlJaroudi WW, Hage FG, Nanda NC. Renal artery fibromuscular dysplasia is a cause of refractory hypertension in the elderly. Echocardiography 26(1), 109-110 (2009).
55. Birrer M, Do DD, Mahler F, Triller J, Baumgartner I. Treatment of renal artery fibromuscular dysplasia with balloon angioplasty: a prospective follow-up study. Eur. J. Vasc. Endovasc. Surg. 23(2), 146-152 (2002).
56. Balk E, Raman G, Chung M et al. Effectiveness of management strategies for renal artery stenosis: a systematic review. Ann. Intern. Med. 145(12), 901-912 (2006).
57. Cooper CJ, Murphy TP, Matsumoto A et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am. Heart J. 152(1), 59-66 (2006).
58. Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int. 69(6), 967-973 (2006).
59. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch. Intern. Med. 151(9), 1786-1792 (1991).
60. Goessens BM, Visseren FL, Olijhoek JK, Eikelboom BC, van der Graaf Y. Multidisciplinary vascular screening program modestly improves the medical treatment of vascular risk factors. Cardiovasc. Drugs Ther. 19(6), 429-435 (2005).
61. Kikuya M, Ohkubo T, Asayama K et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension 45(2), 240-245 (2005).
62. Staessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA 282(6), 539-546 (1999).
63. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 39(5), 982-988 (2002). • Supports occult volume expansion as a mediator of antihypertensive drug resistance.
64. Graves JW, Bloomfield RL, Buckalew VM Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am. J. Med. Sci. 298(6), 361-365 (1989).
65. Vlase HL, Panagopoulos G, Michelis MF. Effectiveness of furosemide in uncontrolled hypertension in the elderly: role of renin profiling. Am. J. Hypertens. 16(3), 187-193 (2003).
66. Ernst ME, Carter BL, Goerdt CJ et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47(3), 352-358 (2006).
67. Investigators A. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288(23), 2998-3007 (2002).
68. Investigators S. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 265(24), 3255-3264 (1991).
69. Sica DA. Chlorthalidone: has it always been the best thiazide-type diuretic? Hypertension 47(3), 321-322 (2006).
70. Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N. Engl. J. Med. 355(4), 385-392 (2006).
71. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008). •• Important recent study demonstrating the superiority of a benazepril/amlodipine combination over a benazepril/ hydrochlorothiazide combination in reducing cardiovascular events in high-risk hypertensive patients.
72. Materson BJ, Reda DJ, Cushman WC, Henderson WG. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J. Hum. Hypertens. 9(10), 791-796 (1995).
73. Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 28(1), 109-114 (1996).
74. Stergiou GS, Skeva, II, Baibas NM et al. Additive hypotensive effect of angiotensinconverting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. J. Cardiovasc. Pharmacol. 35(6), 937-941 (2000).
75. Stergiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A. Comparison of antihypertensive effects of an angiotensinconverting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J. Hypertens. 23(4), 883-889 (2005).
76. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547-1559 (2008). •• Important study showing that a combination of telmisartan and ramipril is associated with a greater number of adverse events without significant benefit as opposed to use of either drug alone in high-risk diabetic patients or those with vascular disease.
77. Townsend RR, DiPette DJ, Goodman R et al. Combined α/β-blockade versus β1-selective blockade in essential hypertension in black and white patients. Clin. Pharmacol. Ther. 48(6), 665-675 (1990).
78. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J. Hypertens. 22(11), 2217-2226 (2004).
79. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin. Exp. Pharmacol. Physiol. 21(4), 315-318 (1994).
80. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49(4), 839-845 (2007).
81. Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. Am. J. Hypertens. 15(4 Pt 1), 333-339 (2002).
82. Flack JM, Oparil S, Pratt JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. 41(7), 1148-1155 (2003).
83. Pitt B, Reichek N, Willenbrock R et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108(15), 1831-1838 (2003).
84. Saha C, Eckert GJ, Ambrosius WT et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 46(3), 481-487 (2005).
85. Bansal N, Tendler BE, White WB, Mansoor GA. Blood pressure control in the hypertension clinic. Am. J. Hypertens. 16(10), 878-880 (2003). • Shows that attendance at a hypertension clinic significantly impacts blood pressure control. 86 Black HR, Bakris GL, Weber MA et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J. Clin. Hypertens. (Greenwich) 9(10), 760-769 (2007).
86. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373(9671), 1275-1281 (2009).
87. Illig KA, Levy M, Sanchez L et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter Phase II Rheos feasibility trial. J. Vasc. Surg. 44(6), 1213-1218 (2006).